How many investments has Monograph Capital Partners made?

Monograph Capital Partners has 23 tracked investments, 2 of which have exited, including 4 dated in the last 24 months.

What stage does Monograph Capital Partners invest at?

Monograph Capital Partners invests at the Seed, Series A, Series B stages.

What sectors does Monograph Capital Partners focus on?

Monograph Capital Partners focuses on Biotech, Healthtech, Medical Devices.

Where is Monograph Capital Partners located?

Monograph Capital Partners is headquartered in London, GB.

Does Monograph Capital Partners lead rounds?

Yes, Monograph Capital Partners leads investment rounds.

Who does Monograph Capital Partners co-invest with?

Monograph Capital Partners most often shares deals with LifeArc Ventures, New Enterprise Associates (NEA), ARCH Venture Partners, among 42 tracked co-investors.

Monograph Capital Partners

Venture capital

London · Seed–Series B · 23 people tracked

Also known as MONOGRAPH CAPITAL ADVISORS (UK), LLP · MONOGRAPH CAPITAL ADVISORS, L.P.

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Monograph Capital Partners

4,142 people in our graph share verified history with the Monograph Capital Partners team — schools, employers, funds. One of them is your warm intro.

Hannah Sealunlockedknows Tim Funnell · together at University of Cambridge (overlapped)

knows the team · via University of Chicago

knows the team · via The University of Edinburgh

knows the team · via McKinsey & Company

knows the team · via New Enterprise Associates (NEA)

knows the team · via Harvard Business School

✨ Fox Verdict

Investment thesis

Monograph Capital invests in innovative life sciences companies with the goal of turning promising science into life-changing treatments for patients worldwide. The firm operates as a transatlantic team focused on sourcing leading scientific innovation and supporting company development across geographic boundaries. It combines differentiated deal sourcing, long-standing relationships with pharmaceutical companies, deep medical expertise, and seasoned operating experience to build strong companies and create value for both company partners and investors, ultimately aiming to improve patient health outcomes over time.

Invests inBiotech Healthtech Medical Devices Europe London North America San Francisco Singapore United Kingdom United States

Source: firm website, verified Sep 15, 2026.

Stage

Seed–Series B

London, GB

Leads rounds

Leads

Instruments

Equity

Founded

2021

Last 12 months

3 investments

Private fund assets

$325.5M

VC funds

Tracked investments

Acquisitions

Team · 23 people

from the firm's website & curated & public directories

Charles Conn· Partner· United Statesin

Partner and co-founder of Monograph focused on tech-enabled services businesses. Former CEO of Oxford Sciences Innovation and founding CEO of Ticketmaster-Citysearch; chairs Patagonia and previously led the Rhodes Trust.

c•••@monograph.bioreveal

Fred Cohen· Partner and Chairman· San Francisco, California, United Statesin

Founder and Investment Committee member of Monograph, which he co-founded in 2021. Previously co-founded Vida Ventures and was Managing Partner at TPG Biotechnology, and earlier a professor at UCSF.

f•••@monograph.bioreveal

Tim Funnell· Partner· London, England, United Kingdomin

Partner and co-founder of Monograph. Previously co-founded MiroBio and built companies at Syncona, Third Rock Ventures and Oxford Sciences; began his career at Boston Consulting Group.

t•••@monograph.bioreveal

Matt McAviney· Partner· San Franciscoin

Partner in Monograph's San Francisco office focused on company formation and early-stage biopharma investing. Previously spent over 10 years at NEA and F-Prime Capital and has helped form 30+ biotech companies.

Mike LaGatta· Partner and COO· Fort Worth, Texas, United Statesin

Partner and Chief Operating Officer at Monograph. Previously General Counsel of TPG Holdings and Chief Tax Officer of TPG, with over 20 years of investment management experience.

Travis Murdoch· Partner

t•••@monograph.bioreveal

Seth Cassel· Partner· Miami, Florida, United Statesin

Founder of Every Mundo and chair of the board of directors.

Bonnie van Wilgenburg· Principal

b•••@monograph.bioreveal

Freddie Dear· Principal (Portfolio)· Londonin

Principal at Monograph who was part of the founding team of portfolio company Ascend Advanced Therapies and sits on the board of Nocion Therapeutics. Previously an Investment Partner at Syncona and part of the Wellcome Trust investment team.

f•••@monograph.bioreveal

Jaideep Dudani· Principal (Portfolio)· San Francisco, California, United Statesin

Principal at Monograph and founding CEO of portfolio company Ouro Medicines. Previously part of the founding team of HI-Bio, worked at Relay Therapeutics, and was the first associate at Vida Ventures.

j•••@monograph.bioreveal

Melisa Guven· Principal· Londonin

Principal in Monograph's London office leading investments in therapeutics and pharmaceutical services. Board observer at Elevara Medicines, Maxion Therapeutics and Prolynx; previously an Engagement Manager at L.E.K. Consulting.

m•••@monograph.bioreveal

Brandi O'Donnell· Chief of Staff & Executive Assistant

Chief of Staff and Executive Assistant to Fred Cohen. Previously supported multiple senior leaders at TPG including Co-CEO Jon Winkelried and Senior Advisors. Earlier career at Santa Fe Film Festival, Doha Film Institute, and America's Cup before transitioning to private equity and venture capital.

Brandi O’Donnell· Chief of Staff & EA· San Francisco Bay Areain

Chief of Staff and EA to Fred Cohen. Previously supported leaders at TPG including Co-CEO Jon Winkelried, with an earlier career spanning film festivals and events.

Daniel Schwarz· Chief Financial Officer· Fort Worthin

Chief Financial Officer of Monograph, based in Fort Worth, leading financial operations, fund administration and reporting. Previously CFO/COO at Bios Partners and Associate Director at Crestline Investors.

Jennifer Shah· Head of Capital Formation· United Statesin

Head of Capital Formation leading fundraising and investor relations. Previously led fundraising and IR at Silver Lake and was a Director of Capital Raising at SoftBank Investment Advisers.

Jeremias Reich· Associate· London

Associate in Monograph's London office supporting sourcing, diligence and portfolio work. Previously a Consultant in McKinsey's Life Sciences practice and a Biotech Investment Analyst at NB Capital; trained as a physician.

Kristina Nebel· US Operations Manager· San Franciscoin

US Operations Manager in Monograph's San Francisco office with extensive experience supporting biotech C-suite executives, including at Walking Fish Therapeutics, Frontier Medicines and CODA Biotherapeutics.

Michelle He· Associate· San Francisco

Secondee Associate in Monograph's San Francisco office supporting investment activities in life sciences. Previously an Investment Manager at Tin Alley Ventures and started her career at Goldman Sachs.

Oscar Molina· Associate· San Franciscoin

Associate in Monograph's San Francisco office supporting sourcing, diligence and portfolio work across life sciences. Previously a Fellow at Longitude Capital.

Ramone Kersey· UK Head of Operations· Londonin

UK Head of Operations in Monograph's London office, combining operational oversight with executive support. Previously supported senior leaders at UnitedHealth Group and worked as a communications specialist at McKinsey.

Charlie Zhou· Investor· Londonin

Investment Manager in Monograph's London office (listed as Advisor, in Portfolio) leading new investments and supporting portfolio companies. Founding member of Ouro Medicines and board director at RegASK; previously at Bain & Company and a practicing physician.

c•••@monograph.bioreveal

Michelle He· Associate· San Francisco, California, United Statesin

Michelle He is an investment manager focused on innovation in medicine and drug discovery, with an interest in biologics and emerging treatment modalities, and in partnering with academics to commercialize their research. She began her career in the investment banking division at Goldman Sachs on the Natural Resources team, and later worked on the investment team at BGH Capital and the Strategy & Operations team at FrankieOne. She holds a Bachelor of Science in Neuroscience from the University of Melbourne.

m•••@tinalleyventures.comreveal

Pradyuman Agarwal· Associate· Mumbai, Maharashtra, Indiain

Pradyuman Agarwal joined Evolvence Equity Partners as an Analyst on the Investments team in 2026, where he evaluates investment opportunities and supports transaction execution. Before this role, he held internships at Roots Ventures, Modulus Alternatives, and Evolvence, working on sector research, investment theses, and live deals. He holds a Dual Degree (B.Tech. + M.Tech.) in Electrical Engineering from IIT Bombay and has cleared CFA Level I.

Founder mafia

3 people who came through Monograph Capital Partners went on to found or lead other companies.

Tim FunnellPartnerFounded Ascend Advanced Therapies Jaideep DudaniPrincipal (Portfolio)Founded Ouro Medicines Kristina NebelUS Operations ManagerFounded Walking Fish Therapeutics

What they invest in

from 15 of 23 portfolio companies

Biotech ×13Healthtech ×10Medical Devices ×8Deep Tech ×3Digital Health ×3AI & Machine Learning ×2SaaS ×2Enterprise Software ×1

HQs:United States×7United Kingdom×3Germany×1

Who they back

founder profiles across 9 portfolio companies

56%

solo founders

5 of 9 mapped founding teams

20%

repeat founders

of 10 founders with career history

Founding team size:solo founder×52 founders×33 founders×1

Where their founders worked beforefrom 10 founders with career history

King's College London ×2

Investments · 23 tracked

founders shown can be your intro path

By year:2026 · 1 2025 · 3 2024 · 1 2023 · 2 2022 · 29 dated

Elevaraelevara.com inOct 2025 · $70M✓ verified

Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.

BiotechHealthtechMedical DevicesLondon, GB

Emma Tinsley(Founder & former CEO (now Non-Executive Director))in Mai-Britt Zocca(CEO)in

Co-investorsSofinnova Partners Forbion

Maxion Therapeutics Websitemaxiontherapeutics.com in 𝕏✓ verified

Maxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs.

BiotechHealthtechCambridge, GB

John McCafferty(Co-founder and CTO)inAneesh Karatt-Vellatt(Co-founder and CSO)in

Co-investorsLifeArc Ventures General Catalyst Solasta Ventures

Nocion Therapeuticsnociontx.com in 𝕏Dec 2025

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.

BiotechHealthtechMedical DevicesWatertown, US

MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in

Board seat Freddie Dear· per SEC Form D

Co-investorsCanaan Partners F-Prime Capital Mission Biocapital OUP (Osage University Partners)Osage University Partners

Ascend Advanced Therapiesascend-adv.com in

Ascend is a gene-to-GMP development partner that helps life-science companies advance advanced therapy products from the research bench through clinical stages.

BiotechHealthtechMedical DevicesMunich, DE

Evis Hursever(Executive Officer)Wesley McConnell(Executive Officer)Michael Stella(Executive Officer, Director)William Hawkins(Executive Officer)

BoardMichael Beecham(Director)Andrew Kozlov(Director)

Co-investorsCathay Health DCVC (Data Collective)Digitalis Ventures

Autobahn Therapeutics, Inc.autobahntx.com inJun 2024

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.

BiotechDeep TechMedical DevicesSan Diego, US

Kevin Finney(Chairman, President and CEO)in John Borkholder(Executive Officer)in

Board Kristina Burow(Director)in Thomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)

Co-investorsARCH Venture Partners Canaan Partners Pfizer Venture Investments Samsara BioCapital Newpath Partners

AviadoBio Websiteaviadobio.com in 𝕏

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

BiotechDeep TechDigital HealthHealthtech

Chris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)inDo Young Lee(Co-Founder)Youn Bok Lee(Co-Founder)in Lisa Deschamps(Chief Executive Officer)in Graeme Fielder(Chief Operating Officer)inAlex Bloom(Chief Development Officer)in

Co-investorsAdvent Life Sciences Dementia Discovery F-Prime Capital LifeArc Ventures New Enterprise Associates (NEA)

CV Therapeuticsgilead.com in 𝕏

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin

Co-investorsAisling Capital Asset Management Company Frazier Life Sciences Kleiner Perkins Longitude Capital Lumira Ventures +5 more

HI-Biohibio.comNov 2022acquired by Biogen

Biotech company developing antibodies to treat autoimmune and inflammatory diseases.

Co-investorsArkin Capital Jeito Capital Alpha Wave Global ARCH Venture Partners Viking Global Investors

Odaiaodaia.ai inMay 2023 · $34M

ODAIA offers Marketing Intelligence, a platform for pharmaceutical marketing and sales teams that ties channel-level actions to prescription (Rx) outcomes and coordinates healthcare provider (HCP) engagement across digital and field channels.

AI & Machine LearningDigital HealthHealthtechMarketing TechSaaSSales Tech

Philip Poulidis(Founder)in

Co-investorsGraphite Ventures Panache Ventures Stand Up Ventures Threshold Ventures Toronto Innovation Acceleration Partners Wittington Ventures +5 more

Ollin Bioollin.bio in 𝕏

Ollin Biosciences is a clinical-stage biopharmaceutical company that acquires and develops therapies for vision-threatening eye diseases, including wet age-related macular degeneration, diabetic macular edema, and thyroid eye disease.

BiotechMedical Devices

Co-investorsAndreessen Horowitz TCG Crossover

Ouro Medicinesouromedicines.com inJan 2025 · $120M

Ouro Medicines is a biotechnology company developing cell-depleting therapies aimed at resetting the immune system to treat chronic immune-mediated diseases such as autoimmune and autoinflammatory conditions.

BiotechHealthtechSouth San Francisco, US

Jaideep(Founding Chief Executive Officer)Neely Mozaffarian(Chief Medical Officer)inChristina(General Counsel & Chief Operating Officer)

Co-investorsNew Enterprise Associates (NEA)Norwest Venture Partners TPG

Prolynxincprolynxinc.com in 𝕏

Prolynx develops ultra-long-acting therapeutics for obesity and metabolic diseases such as type 2 diabetes, using a hydrogel-based microsphere platform with tunable release linker chemistry to control drug release over extended dosing intervals.

BiotechDeep Tech

Gary Ashley(Co-Founder)inDaniel Santi(Co-Founder)inChris Boulton(CEO)inSimon Harnest(Chief Financial Officer)inAmer Mirza(Chief Scientific Officer)inChristian Weyer(Chief Medical Officer)in

Co-investorsOrbiMed

RegASKregask.com in 𝕏Dec 2022 · $10M

RegASK provides an AI-native regulatory intelligence platform that monitors regulatory changes across 160+ markets, orchestrates compliance workflows, and pairs automation with a community of regulatory experts for validation.

AI & Machine LearningEnterprise SoftwareSaaS

Caroline Shleifer(Founder)in

Sudo Biosudobio.com

Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.

BiotechHealthtechMedical DevicesMenlo Park, US

Jim Bristol(Director)Daniel Estes(Director)in Scott Byrd(Executive Officer, Director)in

Co-investorsFrazier Life Sciences Sanofi Ventures SV Health Investors Dementia Discovery Fund Frazier Healthcare Partners TPG

Urogenurogen.com in 𝕏Jul 2023

UroGen is a biotech company developing treatments for urothelial and specialty cancers using a proprietary sustained-release hydrogel platform technology.

BiotechHealthtechMedical DevicesPrinceton, US

Mark Schoenberg, M.D.(Executive Officer)Liz Barrett(President and Chief Executive Officer)inJason Smith(Executive Officer)Arie Belldegrun, M.D.(Director)Dan Wildman(Director)Don Kim(Executive Officer)

Co-investorsAisling Capital Pontifax Venture Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Ollin Biosciences, Inc.AscendAutobahnHuman Immunology BiosciencesMaxion TherapeuticsMiroBioProlynxSudo

Exits · 2

2 acquisitions · showing 1

HI-Bioacq. by Biogen

Portfolio news

latest coverage across their companies

Urogen Pharma stock hits 52-week high at 49.69 USD By Investing.com

Urogen · investing.com · Aug 19, 2026

Ollin Biosciences Raises $330M in Series B Funding

Ollin Biosciences, Inc. · finsmes.com · Jun 24, 2026

Autobahn Therapeutics to Participate in Multiple Upcoming June 2026 Investor Conferences - BioSpace

Autobahn Therapeutics, Inc. · biospace.com · May 27, 2026

About — Nocion Therapeutics - Nocion Therapeutics

Nocion Therapeutics · nociontx.com · Mar 20, 2026

Elevara raises $70M Series A to accelerate RA therapy ELV001 2025

Elevara · inforcapital.com · Oct 24, 2025

Frequently asked questions

How many investments has Monograph Capital Partners made?: Monograph Capital Partners has 23 tracked investments, 2 of which have exited, including 4 dated in the last 24 months.
What stage does Monograph Capital Partners invest at?: Monograph Capital Partners invests at the Seed, Series A, Series B stages.
What sectors does Monograph Capital Partners focus on?: Monograph Capital Partners focuses on Biotech, Healthtech, Medical Devices.
Where is Monograph Capital Partners located?: Monograph Capital Partners is headquartered in London, GB.
Does Monograph Capital Partners lead rounds?: Yes, Monograph Capital Partners leads investment rounds.
Who does Monograph Capital Partners co-invest with?: Monograph Capital Partners most often shares deals with LifeArc Ventures, New Enterprise Associates (NEA), ARCH Venture Partners, among 42 tracked co-investors.

Images

Similar investors

ACT Venture Capital

ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.

$1.1M – $16.2M

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

Breyer Capital

Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.

$500K – $10M

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M